Vitura SA (VTR) AI Stock Analysis

• Market Cap: €82.58M
• Dividend Yield: N/A
• Average Volume (3M): 364.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.28
• Revenue Growth: -7.84%
• EPS Growth: 71.75%
• Country: FR
• Employees: 2
• Sector: Services
• Sector Strength: N/A
• Industry: REIT - Office
• EPS (TTM): -0.58
• Shares Outstanding: 17,087,708
• 10 Day Avg. Volume: 318
• 30 Day Avg. Volume: 364
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: €4.50 ▼(-18.92% Downside)
• Action: Upgraded Date: 04/09/26
• Date: Action: Upgraded 04/09/26

The score is constrained mainly by weak financial performance (ongoing net losses, reduced equity, and high leverage) and a negative P/E that reflects unprofitable earnings. Technicals are supportive of a recent uptrend, but overbought signals temper the near-term outlook.

Positive Factors

Revenue rebound & positive EBIT

A 29.6% revenue rebound and a return to positive EBIT in 2025 indicate improving core operational performance and demand for the office portfolio. This suggests the company can generate operating profits sustainably if trends persist, supporting medium-term recovery and operational resilience.

Negative Factors

High financial leverage

Very high leverage relative to equity reduces financial flexibility and increases refinancing and interest-rate sensitivity for an office REIT. If occupancy or rent trends weaken, debt servicing pressure could accelerate equity erosion and constrain investment or dividend policy over the next 2–6 months.

Vitura SA Business Overview & Revenue Model

Company Description

Vitura SA (VTR) is a leading company operating in the healthcare and pharmaceuticals sector, specializing in the development, manufacturing, and distribution of innovative medical products and solutions. The company focuses on enhancing patient ca...

Read more

Vitura SA (VTR) is a leading company operating in the healthcare and pharmaceuticals sector, specializing in the development, manufacturing, and distribution of innovative medical products and solutions. The company focuses on enhancing patient ca...

Vitura SA Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	60.32M	57.87M	76.61M	72.78M	84.92M
Gross Profit	37.76M	32.91M	50.43M	44.14M	63.67M
EBITDA	21.86M	26.85M	-166.93M	41.01M	45.52M
Net Income	-20.75M	-243.00M	-239.85M	-4.18M	36.93M
Balance Sheet
Total Assets	920.92M	940.47M	1.40B	1.62B	1.66B
Cash, Cash Equivalents and Short-Term Investments	21.64M	13.49M	11.72M	15.17M	57.48M
Total Debt	644.69M	644.20M	855.10M	835.39M	833.49M
Total Liabilities	672.77M	671.57M	883.93M	868.77M	890.52M
Stockholders Equity	248.15M	268.91M	511.91M	755.44M	772.94M
Cash Flow
Free Cash Flow	3.99M	3.83M	-17.45M	-22.70M	-69.37M
Operating Cash Flow	11.38M	12.61M	12.04M	-9.36M	40.90M
Investing Cash Flow	-7.51M	-2.69M	-29.32M	-19.47M	-103.31M
Financing Cash Flow	-1.06M	-8.15M	13.83M	-13.48M	57.05M

Vitura SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.55
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:VTR, the sentiment is Positive. The current price of 5.55 is above the 20-day moving average (MA) of 4.02, above the 50-day MA of 3.91, and above the 200-day MA of 4.76, indicating a bullish trend. The MACD of 0.19 indicates Negative momentum. The RSI at 85.06 is Negative, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:VTR.

Vitura SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COH	73 Outperform	€64.82M	6.23	18.06%	0.55%	6.71%	7.79%
AUB	72 Outperform	€551.06M	19.04	12.71%	2.54%	1.02%	6.31%
ALCGM	60 Neutral	€187.88M	20.05	-5.44%	―	3.79%	-797.10%
ATE	57 Neutral	€1.84B	23.95	6.98%	2.08%	-0.23%	-37.70%
Sector *	55 Neutral	$13.29B	17.42	10.03%	0.93%	7.13%	-12.93%
VTR	44 Neutral	€82.58M	-1.63	-16.98%	―	-7.84%	71.75%
ALCLA	41 Neutral	€38.96M	6.33	―	―	-0.95%	49.19%